Limits...
Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies.

Tang B, Lv J, Li Y, Yuan S, Wang Z, He S - Medicine (Baltimore) (2015)

Bottom Line: Combined relative risks (RRs) were estimated by random-effects models.Sensitivity analyses and publication bias were utilized to evaluate the robustness of our results.No significant associations were observed between the risk of PC and age at menarche (RR = 0.94, 95% confidence interval [CI] 0.83-1.07), age at menopause (RR = 0.98, 95% CI 0.85-1.13), hysterectomy (RR = 0.97, 95% CI 0.84-1.11), oophorectomy (RR = 1.02, 95% CI 0.82-1.26), hormone replacement therapy (RR = 0.97, 95% CI 0.87-1.08), and oral contraceptives (RR = 1.09, 95% CI 0.96-1.23).

View Article: PubMed Central - PubMed

Affiliation: From the Department of Hepatobiliary Surgery (BT, SY, ZW, SH), Affiliated Hospital of Guilin Medical University; Laboratory of Liver Injury and Repair Molecular Medicine (BT, SH), Guilin Medical University, Guilin; Department of Infectious Diseases (JL), People's Hospital of Beihai, Beihai; and Department of Medical Oncology (YL), Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

ABSTRACT
The objective of this study was to assess the relationship between female hormone and menstrual factors and pancreatic cancer (PC) through a meta-analysis of observational studies. We undertook a systematic literature search up to July 10, 2014 in PubMed and EMBASE databases. Combined relative risks (RRs) were estimated by random-effects models. Subgroup analysis was performed by study design, source of control, and geographic regions. Sensitivity analyses and publication bias were utilized to evaluate the robustness of our results. A total of 27 case-control and cohort studies were retrieved for this meta-analysis. No significant associations were observed between the risk of PC and age at menarche (RR = 0.94, 95% confidence interval [CI] 0.83-1.07), age at menopause (RR = 0.98, 95% CI 0.85-1.13), hysterectomy (RR = 0.97, 95% CI 0.84-1.11), oophorectomy (RR = 1.02, 95% CI 0.82-1.26), hormone replacement therapy (RR = 0.97, 95% CI 0.87-1.08), and oral contraceptives (RR = 1.09, 95% CI 0.96-1.23). This meta-analysis of observational studies does not support the hypothesis that exogenous hormone use and menstrual factors are associated with PC.

Show MeSH

Related in: MedlinePlus

Forest plots of hysterectomy and PC risk. CI = confidence interval, PC = pancreatic cancer, RR = relative risk.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554173&req=5

Figure 4: Forest plots of hysterectomy and PC risk. CI = confidence interval, PC = pancreatic cancer, RR = relative risk.

Mentions: Twelve reports have evaluated the correlation between hysterectomy and PC risk.4,13–17,21,25,27,30,34,37 The cumulative risk estimates for ever having had a hysterectomy versus never having had 1 was 0.97 (95% CI 0.84–1.11, I2 = 33.4%, PQ = 0.123) (Figure 4).


Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies.

Tang B, Lv J, Li Y, Yuan S, Wang Z, He S - Medicine (Baltimore) (2015)

Forest plots of hysterectomy and PC risk. CI = confidence interval, PC = pancreatic cancer, RR = relative risk.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554173&req=5

Figure 4: Forest plots of hysterectomy and PC risk. CI = confidence interval, PC = pancreatic cancer, RR = relative risk.
Mentions: Twelve reports have evaluated the correlation between hysterectomy and PC risk.4,13–17,21,25,27,30,34,37 The cumulative risk estimates for ever having had a hysterectomy versus never having had 1 was 0.97 (95% CI 0.84–1.11, I2 = 33.4%, PQ = 0.123) (Figure 4).

Bottom Line: Combined relative risks (RRs) were estimated by random-effects models.Sensitivity analyses and publication bias were utilized to evaluate the robustness of our results.No significant associations were observed between the risk of PC and age at menarche (RR = 0.94, 95% confidence interval [CI] 0.83-1.07), age at menopause (RR = 0.98, 95% CI 0.85-1.13), hysterectomy (RR = 0.97, 95% CI 0.84-1.11), oophorectomy (RR = 1.02, 95% CI 0.82-1.26), hormone replacement therapy (RR = 0.97, 95% CI 0.87-1.08), and oral contraceptives (RR = 1.09, 95% CI 0.96-1.23).

View Article: PubMed Central - PubMed

Affiliation: From the Department of Hepatobiliary Surgery (BT, SY, ZW, SH), Affiliated Hospital of Guilin Medical University; Laboratory of Liver Injury and Repair Molecular Medicine (BT, SH), Guilin Medical University, Guilin; Department of Infectious Diseases (JL), People's Hospital of Beihai, Beihai; and Department of Medical Oncology (YL), Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

ABSTRACT
The objective of this study was to assess the relationship between female hormone and menstrual factors and pancreatic cancer (PC) through a meta-analysis of observational studies. We undertook a systematic literature search up to July 10, 2014 in PubMed and EMBASE databases. Combined relative risks (RRs) were estimated by random-effects models. Subgroup analysis was performed by study design, source of control, and geographic regions. Sensitivity analyses and publication bias were utilized to evaluate the robustness of our results. A total of 27 case-control and cohort studies were retrieved for this meta-analysis. No significant associations were observed between the risk of PC and age at menarche (RR = 0.94, 95% confidence interval [CI] 0.83-1.07), age at menopause (RR = 0.98, 95% CI 0.85-1.13), hysterectomy (RR = 0.97, 95% CI 0.84-1.11), oophorectomy (RR = 1.02, 95% CI 0.82-1.26), hormone replacement therapy (RR = 0.97, 95% CI 0.87-1.08), and oral contraceptives (RR = 1.09, 95% CI 0.96-1.23). This meta-analysis of observational studies does not support the hypothesis that exogenous hormone use and menstrual factors are associated with PC.

Show MeSH
Related in: MedlinePlus